Rigel Pharmaceuticals | RIGL - Себестоимость





Себестоимость Изменить Дата
Agenus USD 642K 399K 2025-09
Amgen USD 1.87B 271M 2026-06
Anika Therapeutics USD 11.44M 797K 2025-12
AstraZeneca USD 2.52B 2.73B 2026-06
BioMarin Pharmaceutical USD 276.29M 76.8M 2026-06
Bristol-Myers Squibb USD 7.89B 4.03B 2026-06
Celldex Therapeutics USD 54.2M 8.94M 2025-06
Daiichi Sankyo JPY 124.29B 6.02B 2026-06
Eli Lilly USD 3.27B 309M 2026-06
Halozyme Therapeutics USD 108.68M 67K 2026-06
Heron Therapeutics USD 11.12M 795K 2025-12
Intrexon USD 1.01M 344K 2024-06
Ionis Pharmaceuticals USD 2.74M 261K 2026-06
Karyopharm Therapeutics USD 1.34M 139K 2026-03
Ligand Pharmaceuticals USD 11.31M 59K 2026-06
MacroGenics USD 9.53M 585K 2026-03
Neurocrine Biosciences USD 39.4M 25.6M 2026-06
Pfizer USD 4.09B 498M 2026-06
Regeneron Pharmaceuticals USD 576.5M 92.9M 2026-06
Rigel Pharmaceuticals USD 8.03M 5.22M 2024-09
Sangamo BioSciences 2.42M 1.11M 2024-06
Ultragenyx Pharmaceutical USD 30M 1000K 2026-03
Veracyte USD 42.19M 3.7M 2026-06